

Rural Community Attitudes and Perceptions on Opioid Overdose and Access to Naloxone



Brooke Terkovich BA, Mark Deutchman MD

University of Colorado School of Medicine

Background

- Prior to COVID-19, Opioid Use Disorder (OUD) and opioid-related overdoses were a major public health concern with opioid overdose related death rates increasing¹.
- Rural communities have higher overdose rates than urban areas, as well as tending to underdiagnose and undertreat OUD^{2,3}.
- Additionally, there are higher barriers to receiving FDA approved OUD care in rural areas.
 - Provider-focused restrictions include:
 - Limited number or lack of providers⁴
 - Few opioid specialty clinics in rural communities⁴
 - Lack of available buprenorphine treatment at federally qualified health centers (FQHCs) in rural communities⁴
 - Consumer-focused barriers include:
 - Higher burden of travel on patients
 - Higher perceived cost of care
- Naloxone is available from community-based programs and pharmacies and some states have implemented naloxone access laws that have significantly increased naloxone dispensing rates^{6,7}.
 - Naloxone availability has not increased to match overdose rates⁸.
- For there to be increased naloxone utilization and dispersal in communities, there must be community buy in and willingness of individuals to administer naloxone to someone suspected of having an opioid overdose^{9,10}.
- Individuals in rural communities already face higher barriers to care, including increased travel times and decreased likelihood of policies allowing EMS to administer naloxone, that can impact response times of emergency services 11,12.

Objectives

Obtain a baseline of layperson attitudes towards and understanding of OUD and naloxone in rural Colorado communities.

Methods

- This study utilized a quantitative survey of laypeople within rural communities who hold positions withing community organizations, such as schools, libraries, and post offices.
- The survey was provided to individuals via a QR code through community meetings regarding opioid use disorder and distributed by leaders of community organizations.
- The survey included questions regarding demographics, Likert scales regarding perceptions towards OUD and naloxone, as well as Yes/No and open-ended questions.
 - Likert scale responses were analyzed using a Whitney Mann analysis comparing responses between individuals who identified as working within healthcare compared to lay person responses.
 - Open ended questions were analyzed for recurring themes and again separated based on employment within healthcare compared to other industries as selfreported in the survey.

Results

- 17 individuals responded to the survey
- 12 of the total 17 survey respondents identified as working within the healthcare industry.
- The non-healthcare respondents reported employment in the following industries: primary/secondary education, non-profit organization, government and public administration, and homemaker.






Figure 1.

Demographics of survey respondents as self-reported including age (A.), sex (B.) and industry of employment (C.) and county of residence (D.)



Respondent's prior experience with opioid overdose (A.), naloxone administration (B.) and current Colorado law surrounding the dispensing of naloxone in pharmacies (C. and D.).



The breakdown of individuals in the healthcare field who were aware of MAT in their area prior to the survey (A.) compared to the number of individuals who worked outside of the healthcare field who were aware of MAT services in their area (B.).




Figure 4.

Comparison of healthcare vs non-healthcare respondent answers regarding current status of the opioid overdose crisis severity (A.), beliefs regarding who should have access to and the ability to administer naloxone at the start of the survey (B.), the impacts that broader access to naloxone would have in the community (C.) and

recognize an opioid overdose and administer naloxone.

attitudes regarding confidence and willingness of self and community members to

End of survey responses regarding beliefs around whether naloxone should be available in community spaces and if trained community members should be allowed to administer naloxone. Attitudes Around Naloxone Availablity and Administration in Community Spaces at the End of the Survey Healthcare Non-Healthcare

Results

Conclusions

- Individuals who work in healthcare trended to have more positive attitudes regarding naloxone and higher confidence in their ability to recognize an opioid overdose and appropriately administer naloxone.
- Laypersons who participated in this survey tended to have a lower knowledge regarding OUD, naloxone, and resources available within their community.
- Further administration of the survey across a wider geographic region would be required to be able to draw conclusions regarding how best to educate individuals in rural communities regarding naloxone access and administration.
- The results from this study are not adequately representative to extrapolate ideas regarding the willingness of rural community members to have naloxone within community spaces, similar to AEDs, to be used as needed in case of an opioid overdose.

Limitations

This survey had a low number of responses. This is in part because of the challenges of attempting to administer a survey to individuals in community spaces during COVID-19. An additional limitation is that geographic region of the responses is not equally divided as the majority of the respondents were from Teller County. Those individuals who identified as working in the healthcare industry were only located in Teller County, which may factor into how they responded to the survey compared to individuals working within healthcare in other rural locations in Colorado.

References

- 1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths United States, 2013-2017. (1545-861X (Electronic)).
- 2. Mack, K.A., C.M. Jones, and M.F. Ballesteros, *Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-United States.* (1600-6143 (Electronic)).
- 3. Hallgren, K.A., et al., Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. (1873-6483 (Electronic))
- 4. Lister, J.J., et al., A systematic review of rural-specific barriers to medication treatment for opioid
- use disorder in the United States. (1097-9891 (Electronic)).5. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US
- physicians trained to treat opioid use disorder. *Ann Fam Med.* 2015;13(1):23-26.

 6. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. *Drug and Alcohol*
- 7. Haffajee RL, Cherney S, Smart R. Legal requirements and recommendations to prescribe

Dependence, 2018:189:37-41.

- naloxone. *Drug and Alcohol Dependence*. 2020;209:107896.

 8. Ashburn NP, Ryder CW, Angi RM, et al. One-Year Mortality and Associated Factors in Patients Receiving Out-of-Hospital Naloxone for Presumed Opioid Overdose. *Annals of Emergency*
- Medicine. 2020.9. Hanson BLA-Ohoo, Porter RR, Zold AL, Terhorst-Miller H. Preventing opioid overdose with peer-
- administered naloxone: findings from a rural state. (1477-7517 (Electronic)).

 10.Kilwein TM, Wimbish LA, Gilbert L, Wambeam RA. Practices and concerns related to naloxone use among emergency medical service providers in a rural state: A mixed-method examination.
- Prev Med Rep. 2019;14:100872-100872.

 11.Gulec N, Lahey J, Suozzi JC, Sholl M, MacLean CD, Wolfson DL. Basic and Advanced EMS Providers Are Equally Effective in Naloxone Administration for Opioid Overdose in Northern New England. Prehospital Emergency Care. 2018;22(2):163-169.
- 12.Green TC, Bratberg J, Baird J, et al. Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. *International Journal of Drug Policy.* 2019:102602.

Acknowledgements

I would like to thank Dr. Mark Deutchman, my advisor, for his help and guidance throughout this project.

This study did not receive funding from any source and neither Brooke Terkovich nor Dr. Deutchman have any no conflicts of interest to report.